Overview of Danol

What is Danol and Its Composition?

Danol is a recognized brand name for a prescription-only medication containing the single active ingredient, Danazol. This medication is classified as a synthetic steroid, derived from Ethisterone, meaning it is manufactured through chemical synthesis rather than being a naturally occurring compound. It is prepared as oral capsules for systemic delivery, ensuring the active compound is distributed throughout the body. The active substance, Danazol (chemical formula C22H27NO2), is supplied as a single-ingredient product. Danazol is identified as one of the first pharmacological agents specifically developed to address conditions sensitive to reproductive hormone levels.

The Pharmacological Identity: What Type of Steroid is Danazol?

Danazol is pharmacologically identified as an antigonadotropin, a specialized type of synthetic steroid. This class of medicine functions primarily by suppressing certain hormonal signals that originate in the brain's pituitary gland. The drug is designed to depress the synthesis and release of the key pituitary gonadotropins: Follicle-Stimulating Hormone (FSH) and Luteinizing Hormone (LH).

Pharmacological profiles indicate Danazol's dual action, characterized by its ability to inhibit gonadotropin release while simultaneously having a direct inhibiting effect on ovarian steroidogenesis. Beyond this primary mechanism, Danazol exhibits multiple concurrent weak activities, including characteristics of a progestogen and a weak androgen.

General Purpose and Therapeutic Context

The general purpose of Danol is to create a controlled, low-estrogen internal environment by modulating the hormonal system. This controlled hormonal shift is the mechanism utilized to manage certain hormone-sensitive conditions. A typical use scenario involves managing severe symptoms associated with endometriosis, as well as stabilizing specific plasma protein deficiencies linked to systemic disorders such as Hereditary Angioedema (HAE), demonstrating its application in both gynecological and specialized systemic contexts.

Regulatory References

What side effects are possible with Danol?

Possible Side Effects and Safety Information

The safety profile for Danol is based on official government regulatory documents and includes a range of common side effects, as well as specific serious risks and contraindications.

Serious and Clinically Significant Adverse Reactions

Serious adverse reactions reported in official labeling include thromboembolic events (blood clots in arteries or veins, which may lead to stroke or myocardial infarction), severe liver damage (hepatotoxicity), peliosis hepatis (blood-filled cysts in the liver), and benign hepatic adenoma. A condition known as pseudotumor cerebri (increased pressure around the brain) has also been reported rarely.

Common Adverse Reactions

Many adverse effects are related to the medicine's androgenic (male hormone-like) properties. These are often classified as Common and may include:

Hormone-related effects: Voice changes (hoarseness, deepening pitch), menstrual disturbances (amenorrhea, spotting, alteration of cycle timing), weight gain, and reduction in breast size.
Skin and systemic effects: Acne, oily skin/hair, flushing, sweating, and hirsutism (abnormal hair growth).
Nervous system: Emotional lability and nervousness.

Contraindications and Restrictions

The medicine is strictly contraindicated (must not be used) in patients with specific severe pre-existing conditions or circumstances due to unacceptable risk, including:

Pregnancy and Lactation: Contraindicated due to the risk of virilization in a female fetus and potential adverse effects during breastfeeding.
Thromboembolic Disease: Contraindicated in patients with active or a history of blood clots.
Organ Dysfunction: Contraindicated in patients with severe hepatic, renal, or cardiac dysfunction.
Other conditions: Undiagnosed abnormal genital bleeding, porphyria, and androgen-dependent tumours.

Monitoring of hepatic function and lipid profiles is noted as a necessary safety measure, particularly during long-term exposure, where the risk of certain liver complications may be heightened.

Overdose and Emergency Response

Overdose and When to Seek Help: Official Regulatory Information

Official regulatory documentation on Danazol emphasizes the risk of severe systemic toxicities and specific life-threatening clinical manifestations that require immediate medical attention, rather than detailing an acute overdose syndrome. When an overdose is suspected, or if severe symptoms occur, emergency services must be contacted immediately.

Documented Severe Manifestations

High-dose exposure or toxicity may present with manifestations stemming from severe outcomes, including:

Neurological Distress: Signs of benign intracranial hypertension, such as severe headache, nausea, vomiting, and visual disturbances. The presence of papilledema requires immediate drug discontinuation and urgent referral to a specialist.
Vascular and Hepatic Toxicity: Regulator documents detail the potential for life-threatening or fatal thrombotic events (including stroke) and severe liver complications (e.g., peliosis hepatis), which can lead to acute intra-abdominal hemorrhage.

Mandated Emergency Actions

Individuals must seek medical attention immediately at the first sign of any severe adverse drug reaction. If the person has collapsed, experienced a seizure, or cannot be awakened, emergency services must be called at once.

Supportive Care

Overdose management is symptomatic and supportive, as the official prescribing information states that no specific pharmacological antidote is known. Hospital monitoring is typically required.

Therapeutic Uses of Danol

What Danol Treats: Main Uses and Benefits

Danol (Danazol) is a medication generally used in conditions where symptoms create noticeable physiological strain or are associated with acute or episodic changes. Its application may assist with symptomatic management across relevant therapeutic domains. This medication is commonly used for managing conditions such as endometriosis and is considered relevant for preventing hereditary angioedema attacks.

The core benefit of Danol is associated with its role in addressing symptom clusters that may become intense or disruptive. It is commonly used to help manage chronic and cyclic pelvic pain and associated discomforts like dysmenorrhea. It is also applied when specific conditions produce significant symptomatic burden, such as the cyclical breast pain (mastalgia) and tenderness associated with fibrocystic breast disease. For patients with Hereditary Angioedema, it is relevant for long-term prevention of recurrent swelling attacks, which contributes to maintaining functional stability.

“It is applied in clinical settings that involve acute or unstable symptom patterns, which may assist with maintaining functional stability when symptoms become more noticeable.”

Quick Fact: Support for Chronic Pain and Episodic Swelling
Danol is generally applied in contexts where additional symptomatic support is needed, which contributes to improving day-to-day comfort during symptomatic periods associated with chronic pelvic discomfort and unpredictable HAE attacks.

Regulatory References

DailyMed Label published by the NIH National Library of Medicine

Eligibility and Restrictions for Use

Who Can and Cannot Use Danazol (Danol)? — Official Regulatory Information

Eligibility for Danazol is strictly defined by regulatory documents, focusing primarily on absolute contraindications and mandatory precautions.

Absolute Prohibitions (Contraindications)

Danazol must not be used by the following populations or in the presence of these conditions, as documented by regulatory authorities:

Pregnancy and Breastfeeding: Use is strictly contraindicated due to the risk of virilization (androgenic effects) on a female fetus. A sensitive pregnancy test is required prior to starting therapy.
Organ Function: Individuals with markedly impaired hepatic (liver), renal (kidney), or cardiac (heart) function.
Thromboembolic Disease: Patients with active thrombosis or a history of thromboembolic disease (e.g., blood clots).
Other Conditions: Patients with Porphyria, androgen-dependent tumors, undiagnosed abnormal genital bleeding, or known hypersensitivity to the drug.

Conditional or Restricted Use

Use is subject to special caution or careful observation in specific groups:

Fluid Retention Risks: Patients with conditions potentially affected by fluid retention, such as epilepsy, migraine, hypertension, or cardiac/renal dysfunction, require close monitoring.
Pre-treatment Screening: For women with fibrocystic breast disease, breast carcinoma must be ruled out before therapy begins.
Age: Safety and effectiveness are not established in pediatric patients.

What should I know about interactions with other medicines?

Danol's official regulatory interaction profile is defined by two primary domains: the pharmacokinetic inhibition of clearance of other medicines and systemic pharmacodynamic alteration. The risk and severity of all documented interactions are heightened in patients with markedly impaired hepatic, renal, or cardiac function, where Danol is contraindicated.

Exposure-Altering Interactions

Co-administration with certain medicinal products, including some Statins (HMG-CoA Reductase Inhibitors) such as Simvastatin, increases the risk of serious muscle injury, including rhabdomyolysis, due to the statin's elevated systemic exposure. This pharmacokinetic effect also applies to immunosuppressants: Danol may significantly raise the plasma levels of Cyclosporin and Tacrolimus, potentially increasing their risk of renal toxicity. Similarly, plasma concentrations of Carbamazepine may be increased when co-administered with Danol.

Pharmacodynamic and Substance Interactions

Specific pharmacodynamic interactions require close observation. Danol can potentiate the action of Oral Anticoagulants (e.g., Warfarin), necessitating careful monitoring of the prothrombin time. Furthermore, Danol can induce insulin resistance, which may antagonize the therapeutic action of Antidiabetic Drugs. Its use may also oppose the action of Antihypertensive Agents. An explicit regulatory restriction is noted for Ethyl Alcohol, as co-administration has been reported to cause subjective intolerance, including nausea and shortness of breath.

Mechanism of Action

How Danol Works

Danol exerts its effects primarily by modulating key steroid hormone pathways and regulating endocrine processes. It acts within domains involving receptor- or enzyme-mediated signaling, resulting in modulation within targeted physiological systems.

Modulates Steroid Hormone Receptors

Danol acts as a weak androgen, anti-estrogen, and anti-progestin. It directly binds to androgen receptors to initiate signaling cascades while simultaneously acting as an antagonist at estrogen and progesterone receptors. This dual-action influences the activity of signaling processes driven by steroid patterns, causing altered downstream gene expression and subsequent pathway shifts.

Inhibits Gonadal and Adrenal Enzymes

The drug modifies early molecular steps in steroid biosynthesis. It inhibits several cytochrome P450 enzymes involved in sex hormone production, including P450scc and 17alpha-hydroxylase/17,20-lyase. This enzymatic suppression restricts the synthesis of endogenous hormones, which results in the constrained biosynthesis and systemic concentration of estrogens and progestins.

Suppresses the Hypothalamic-Pituitary-Gonadal (HPG) Axis

Danol reduces the release of gonadotropins—specifically luteinizing hormone (LH) and follicle-stimulating hormone (FSH)—from the pituitary gland. This engagement with mechanisms influences feedback regulation within the HPG axis and causes alterations in the circulating levels of endogenous hormones.

Dosage and Administration Information

How Danol is Used: Official Administration and Dosing

Danol (Danazol) is a medication whose usage is defined by clinical guidelines, ensuring consistent application in clinical practice. The established route of administration for this medication is oral, and it is supplied as capsules in strengths of 50 mg, 100 mg, and 200 mg.

Standard Dosing and Administration Context

The total daily dose of Danol is typically taken in two divided doses (BID) for gynecological conditions. For endometriosis, the dose ranges from 200 mg to 800 mg per day. For fibrocystic breast disease, the daily dose is between 100 mg and 400 mg. For Hereditary Angioedema (HAE), the initial dose is 200 mg, taken two or three times a day (BID or TID).

Administration Rule	Standard Instruction
Timing in Relation to Food	Must be taken with a meal; administration consistency is necessary as a high-fat meal significantly increases absorption.
Dose Initiation	For women, treatment must begin during menstruation to rule out pregnancy.
Treatment Duration	A continuous course of 3 to 9 months is typically required; the dose should be titrated downward to the minimum effective level.
Population Restrictions	Use is not recommended in patients with marked hepatic or renal impairment.

These instructions define the method of intake, the specific doses for approved uses, and the duration patterns that must be followed during the course of therapy. Adherence to these guidelines ensures the drug is administered as intended by established clinical protocols.

Recent Clinical Evidence

The research base for Danol (Danazol) is derived from official clinical studies, focusing on how the medication was studied in the context of its approved indications. The evidence primarily consists of Randomized Controlled Trials (RCTs) for gynaecological conditions and long-term observational data for the management of a rare systemic disorder. Research provides context but not individual predictions.

Evidence for Use in Endometriosis

Primary research utilized RCTs involving premenopausal women with endometriosis. Studies focused on patient-reported outcomes describing perceived discomfort (pelvic pain, dysmenorrhea) and changes in the size and extent of endometriotic lesions. Trials documented measurements of symptomatic change and lesion extent during the study period. However, long-term effects are not fully established regarding the durability of symptomatic patterns once the treatment is stopped. Comparative evidence is lacking against many of the newer pharmacological interventions.

Evidence for Preventing Hereditary Angioedema (HAE) Attacks

Due to the rarity of HAE, evidence includes Controlled Clinical Trials and extensive long-term Observational Studies. Research explored outcomes describing episodic or acute changes, primarily monitoring the frequency of HAE attacks and the need for acute medical intervention. Research describes patterns where the frequency of recorded HAE attacks was observed to vary in patients maintained on continuous therapy. The research base is characterized by small patient numbers and a reliance on observational data.

What Remains Uncertain in the Research Landscape

The research landscape includes several areas where certainty remains low or evidence is limited. For endometriosis and fibrocystic breast disease, follow-up durations were limited. Data for certain groups remain insufficient for a comprehensive analysis, including older adults. Subgroup findings are uncertain due to limited data for special populations. This summary highlights what is known—and what is still uncertain—based on the official research record.

Key Studies & References

Label: DANAZOL capsule - Official FDA Drug Label via DailyMed

Frequently Asked Questions (FAQ)

Common questions about Danol (FAQ)

Q: How quickly does Danol start working?

Regulatory information indicates that the active ingredient, Danazol, typically reaches stable levels in the bloodstream (steady-state) within about 6 to 14 days of twice-daily dosing. However, the time to see the intended therapeutic effect can vary significantly among individuals.

Q: How long do the effects of Danol last after taking a dose?

The body's process for eliminating the medication has been reported to take approximately 24 to 26 hours, although this can vary among individuals. This timeframe reflects how long the active compound is known to remain circulating in the system.

Q: What are the most common side effects people experience with Danol?

Official records list common side effects such as weight gain, acne, hot flushing, and sweating. Additionally, changes in the menstrual cycle, including absent periods (amenorrhea) or spotting, are frequently reported adverse reactions.

Q: Does Danol affect cholesterol levels?

Official warnings note that Danol may cause changes in the body's lipid profile, which includes cholesterol and triglyceride levels. Official safety guidance recommends that lipid profiles be monitored periodically during the course of therapy.

Q: Is it normal for my menstrual cycle to change while taking Danol?

Yes, changes in the menstrual cycle are an expected and common effect of Danol. The medication is known to cause various menstrual disturbances, including the absence of periods (amenorrhea) or changes in the timing and pattern of bleeding, due to its influence on hormones.

Q: Is it okay to drink a small amount of alcohol while on Danol?

The official drug information reports that co-administering Danazol with ethyl alcohol has been known to cause symptoms of intolerance, such as nausea and shortness of breath. Given these reports, it is advisable to discuss alcohol consumption with a healthcare provider.

Q: What are the rare but serious side effects of Danol?

Official warnings highlight several serious risks. These include the potential for severe liver damage (hepatotoxicity, peliosis hepatis) and the formation of blood clots in arteries or veins (thromboembolic events). A rare condition known as pseudotumor cerebri (increased pressure around the brain) has also been reported.

Q: Are the side effects of Danol permanent?

While many side effects are expected to resolve after stopping the medication, regulatory information notes that some androgenic effects. Specifically, voice changes (such as deepening or hoarseness) may not be reversible after the drug is stopped.

Q: Can Danol affect my mood or emotions?

Yes, official safety information indicates that effects on the central nervous system have been reported. These adverse reactions include emotional lability, which refers to noticeable mood swings, as well as feelings of nervousness.

Q: Does Danol cause weight gain, and if so, how much is typical?

Official labeling lists weight gain as a common adverse reaction associated with taking Danol. However, the regulatory documents do not specify the typical amount of weight gain expected.

Q: Is it normal to feel nauseous when starting Danol?

Nausea is not specifically listed as a common, expected side effect when starting Danol. Any new or persistent symptom, including nausea, should be brought to the attention of a healthcare professional.

Q: Does Danol interact with common pain relievers like ibuprofen?

The official interactions list warns about medications such as oral anticoagulants, but does not specify interactions with common non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen. It is important to inform a healthcare provider about all medicines and supplements being taken.

Q: Are there any specific foods or drinks to avoid while taking Danol?

Danazol capsules must be taken with a meal to ensure the body absorbs the medicine effectively. Beyond this requirement, the only specific substance noted to cause an intolerance reaction in the labeling is ethyl alcohol.

Q: Can men take Danol for any condition?

Yes, the medication is officially indicated for conditions that affect both sexes. Danol is approved for the prophylactic (preventative) treatment of attacks related to Hereditary Angioedema (HAE), a condition not exclusive to women.

Q: Is Danol suitable for adolescents?

Official regulatory documents explicitly state that the safety and effectiveness of Danol have not been established in pediatric patients. Its use in adolescents and children must be assessed by a doctor.

Q: Is Danol meant to be taken long-term or short-term?

The required duration of therapy depends on the condition being treated. For conditions like endometriosis, a continuous course of 3 to 9 months is typically required. For the prevention of Hereditary Angioedema (HAE) attacks, it is often used for long-term prophylaxis (prevention).

Q: Is Danol used to treat conditions other than its primary use?

The medication is officially approved and labeled for three main conditions: endometriosis, fibrocystic breast disease, and Hereditary Angioedema (HAE). Its regulatory indications are limited to these specific uses.

Q: Does the time of day matter when taking Danol?

Official instructions specify that the total daily dose should be taken in two divided doses (BID) and always with a meal for proper absorption. While no specific morning or evening time is mandated, consistency with meal times is important.

Q: Are there any age restrictions for taking Danol?

Safety and efficacy are not established in children or adolescents. For older adults, the official labeling notes that clinical experience in this group is limited. A doctor assesses suitability based on these factors.

Q: Does Danol have any effect on blood pressure?

The medication has been associated with effects such as fluid retention in the body. This fluid retention may potentially affect blood pressure and can oppose the action of drugs taken to lower blood pressure (antihypertensive agents).

Q: Can Danol be used during perimenopause?

While Danol is indicated for endometriosis, which typically affects premenopausal women, official regulatory labeling does not provide specific guidance regarding the use of Danol exclusively during the perimenopausal transition.

Q: What is the typical timeframe for seeing benefits from Danol?

For treating endometriosis, patients are typically required to take a continuous course of treatment lasting 3 to 9 months. Symptomatic improvement is monitored throughout this period.

Q: What kind of improvements can I realistically expect from Danol?

Studies and official information indicate that for endometriosis, expected improvements include the reduction of pain (such as pelvic pain and painful periods) and the regression of endometriotic lesions. For Hereditary Angioedema, the expected outcome is the prevention of acute attacks.

Q: Is Danol considered a first-line treatment for its primary indication?

Clinical guidelines often describe Danol as an alternative agent or a second-line therapy for its approved uses, rather than a primary treatment choice.

Q: Does taking Danol require regular follow-up with a specialist?

The requirement for periodic monitoring of hepatic function (liver tests) and lipid profiles suggests the need for ongoing medical supervision during therapy.

How should Danol be stored and disposed of?

Official Storage and Disposal Requirements

The storage and disposal instructions for Danol (danazol) capsules are strictly defined by regulatory labeling to maintain the product's quality and ensure safe handling.

Requirement Type	Official Condition
Temperature	Store at Controlled Room Temperature (20 C to 25 C / 68 F to 77 F).
Environmental Protection	Protect the medicine from moisture and excessive heat; keep in the original container.
Child Safety	Mandatory to keep Danol out of the reach and sight of children.
Disposal	Do not flush unused or expired capsules down the toilet or pour into a drain. Disposal must follow procedures for pharmaceutical waste, such as a medicine take-back program.

These conditions ensure the stability of the Danazol active ingredient and specify that the product must not be introduced into wastewater systems.

Danol